An open phase I study to assess the relationship between multiple doses of the MM120 solution to be ingested and subjective effects in healthy volunteers
Résumé de l'étude
Mind Medicine Inc. (MindMed) is developing a form of D-Lysergsäurediethylamid (LSD) called MM120 for the treatment of generalized anxiety disorder (GAD). MM120 (LSD-D-Tartrate) is an ingestible hallucinogen. The sponsor has conducted three clinical studies with MM120. In a large-scale study, the efficacy of MM120 was demonstrated in patients with GAD. The purpose of the MM120-103 study is to assess the possibility of increasing the MM120 dose from 20 micrograms to 100 micrograms without changing the drug's effect. This study, which will be conducted at a single Swiss hospital, will enroll up to twenty healthy volunteers. During the study, participants will undergo clinical tests to ensure their eligibility for MM120 administration. This phase of the study is called screening. If everything is in order, participants will receive MM120 at the lowest dose. Depending on how well they tolerate the dose, they may receive higher doses of MM120. The study lasts up to 43 days, including 21 days for screening, up to 8 days for dosing, and 14 days for subsequent safety assessments. Based on the results of this study, follow-up studies will be conducted to examine whether MM120 continues to provide the same benefits when the perceptible effects of the drug are reduced.
(BASEC)
Intervention étudiée
Mind Medicine Inc. (MindMed) is developing a form of D-Lysergsäurediethylamid (LSD) called MM120 for the treatment of generalized anxiety disorder (GAD). MM120 (LSD-D-Tartrate) is an ingestible hallucinogen.
(BASEC)
Maladie en cours d'investigation
Only healthy volunteers are participating in this study. The development of the investigational drug MM120 aims to treat generalized anxiety disorder (GAD).
(BASEC)
1. At Visit 1: Participants aged 18 to 65 years inclusive. 2. Healthy, as determined by a physician (or designee) based on medical history and all eligibility assessments. 3. Suitable venous access for cannulation and repeated blood sampling. (BASEC)
Critères d'exclusion
1. Women of childbearing potential who do not wish or cannot use a highly effective contraceptive method for the duration of the study (from screening to the last visit of the participant), OR Men who are physiologically capable of fathering a child and are sexually active with a woman of childbearing potential, but do not wish or cannot use a mechanical barrier method for contraception (e.g., condoms with or without spermicide cream or gel; the fertile partner must be asked to use a highly effective contraceptive method from screening to the last visit of the participant). 2. Women who are currently pregnant or breastfeeding or who wish to become pregnant or breastfeed during the study. 3. Sperm or egg donation or retrieval during the study. (BASEC)
Lieu de l’étude
Bâle
(BASEC)
Sponsor
Mind Medicine Inc. Stimolo Pharma Consulting GmbH
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Shelly Bustion
+41 79 2477143
sbustion@cluttermindmed.coMind Medicine Inc.
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
17.07.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Phase 1, Open-label Study Evaluating Relationship Between Multiple Doses of MM120 Oral Solution and Subjective Effects in Healthy Volunteers (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
mm120-103-lay-language-summary-de-ch.pdfLien vers les résultats dans le registre primaire
non disponible